Stryker’s 2010 Innovator of the Year Brian Hess Joins InVivo Therapeutics as Director of Product Development
February 22 2012 - 6:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV),
announced today that former Stryker biomaterials product
development specialist, Brian Hess, has joined InVivo as its
Director of Product Development.
As Director of Product Development, Hess will be managing,
developing and maintaining the pipeline for the entire portfolio of
InVivo products. Hess will lead the translation of InVivo’s
technologies from research and development through clinical trials
and into production manufacturing by developing specifications,
protocols and reports.
Prior to joining InVivo Therapeutics, Hess spent the past eight
years at Stryker developing biomaterial technologies for the
orthopedic market, and he has led multiple product development
teams through the FDA process. Hess was instrumental in developing
HydroSetTM, an injectable calcium phosphate based bone substitute,
from concept to product launch. The product has become the
market-leading bone scaffold, and Stryker awarded Hess and his team
with “Best Technology” and “Best Team Synergy” for their work on
this critical product.
“I’ve been impressed with the cutting-edge work from the InVivo
Therapeutics team on the development of the biopolymer scaffold
technologies and the impact it can have on the future of
neurological treatments,” Hess said. “I am honored to join the team
to help bring this product and others in the research and
development phase to market.”
Hess also won several research and development awards during his
tenure at Stryker. Most notably he was named "Co-Innovator of the
Year" in 2010 within Stryker Orthopeadics for his work on a novel
bone adhesive technology that has the potential to replace metal
fixation in the body and revolutionize the orthopedic fixation
market. He spent the past three years working with his team
demonstrating its feasibility and safe use as his program grew to a
team of more than 25 engineers and scientists.
InVivo Chief Executive Officer Frank Reynolds said, “We believe
Brian’s past successes in the medical device industry will lead the
commercialization of the three products we intend to have under
review at FDA this year, as well as help to bring our portfolio of
products for other neurological conditions successfully to the
market in the coming years.”
For more information about InVivo Therapeutics’ technologies,
visit www.invivotherapeutics.com.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is focused on utilizing
polymers as a platform technology to develop treatments to improve
function in individuals paralyzed as a result of traumatic spinal
cord injury. The company was founded in 2005 on the basis of
proprietary technology co-invented by Robert Langer, ScD. Professor
at Massachusetts Institute of Technology, and Joseph P. Vacanti,
M.D., who is affiliated with Massachusetts General Hospital. In
2011, the company earned the prestigious David S. Apple Award from
the American Spinal Injury Association for its outstanding
contribution to spinal cord injury medicine. The publicly traded
company is headquartered in Cambridge, Mass. For more details,
visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
within the meaning of the federal securities laws. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company’s
ability to sell additional shares of common stock and warrants to
purchase common stock at additional closings, the Company’s ability
to develop, market and sell products based on its technology; the
expected benefits and efficacy of the Company’s products and
technology in connection with spinal cord injuries; the
availability of substantial additional funding for the Company to
continue its operations and to conduct research and development,
clinical studies and future product commercialization; and, the
Company’s business, research, product development, regulatory
approval, marketing and distribution plans and strategies. These
and other factors are identified and described in more detail in
our filings with the SEC, including our Form 10-K and Form 10-Qs
and our current reports on Form 8-K. We do not undertake to update
these forward-looking statements made by us.